2003, Leads and Pharmaceutical research

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Leads

Pharmaceutical research

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Andrea Pfeifer, PhD In 2003, Andrea Pfeifer co-founded AC Immune SA.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Innovations & Challenges in Brain Health

PM360

NOVEMBER 12, 2024

One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. Before Sage, he served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003.

Food and Drug Administration

Food and Drug Administration Healthcare Provider Healthcare Healthcare

Webinars

The Intersection of AI and Sales: Personalization Without Compromise

MORE WEBINARS

Pharma Rep Focus

Paving the way for anti-Abeta active immunotherapy

Innovations & Challenges in Brain Health

Webinars

Stay Connected